Immortagen, Inc. Completes Series A Financing for Personalized Medicine

CORALVILLE, Iowa, Sept. 19, 2016 /PRNewswire/ -- Immortagen, Inc. announced today that it has successfully completed its Series A financing.  Immortagen is a cutting edge cancer company that is developing genetic analysis tools for personalized medicine.  These proprietary tools will assist pharmaceutical and diagnostics companies to interpret next-generation genetic data and guide clinical trial design and recruitment.  Immortagen's product pipeline fills a key gap as more and more patient tumors are sequenced, and genetic analysis of the data is required.  Founded by a team of leading physician-researchers and complemented with proven management, Immortagen believes it will fill a key gap in the global oncology market.

Related Files

ImmortaPressFinl for Series A 8-1-16-1-2.docx

This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com

SOURCE Immortagen, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED